Abstract
Children are consistently reported to have reduced SARS-CoV-2 infection rates and a substantially lower risk for developing severe COVID-19. However, the molecular mechanisms underlying protection against COVID-19 in younger age groups remain widely unknown. Here, we systematically characterized the single-cell transcriptional landscape in the upper airways in SARS-CoV-2 negative and age-matched SARS-CoV-2 positive children (n=42) and corresponding samples from adults (n=44), covering an age range of four weeks to 77 years. Children displayed higher basal expression of the relevant pattern recognition receptor (PRR) pathways in upper airway epithelial cells, macrophages, and dendritic cells, resulting in stronger innate antiviral responses upon SARS-CoV-2 infection compared to adults. We further detected distinct immune cell subpopulations with an overall dominance of neutrophils and a population of cytotoxic T cells occurring predominantly in children. Our study provides evidence that the airway epithelial and mucosal immune cells of children are pre-activated and primed for virus sensing, resulting in a stronger early innate antiviral responses to SARS-CoV-2 infection compared to adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the BIH COVID-19 research program and the fightCOVID@DKFZ initiative, the European commission (ESPACE, 874719, Horizon 2020), the German Federal Ministry for Education and Research (BMBF) - funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI; 031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B), the BMBF-funded Medical Informatics Initiative (HiGHmed, 01ZZ1802A - 01ZZ1802Z), the BMBF-funded projects 01IK20337, 82DZL0098B1, the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)-funded CRC-TR 84 B08, CRC-1449 Z01, CRC-TR 179 TP11 and the DFG COVID-19 focus funding project BI1693/2-1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the respective institutional ethics committees of either the Charite-Universitatsmedizin Berlin (EA2/066/20, EA2/066/20) or the University Medical Center Leipzig (123/20-ek) and conducted in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to potential risk of de-identification of pseudonymized RNA sequencing data the raw data will be available under controlled access in the EGA repository, [will be added upon completion of peer review/ acceptance]. Count and metadata tables (patient-ID, sex, age, cell type, QC metrics per cell) can be found at FigShare: [will be added upon completion of peer review/ acceptance]. In addition, these data can be further visualized and analyzed in the Magellan COVID-19 data explorer at https://digital.bihealth.org [will be publicly available upon completion of peer review/ acceptance].
